Innohep

Tinzaparin sodium, the active ingredient in Innohep, is a low molecular weight heparin presented as an injection solution for intravenous and subcutaneous use. It treats and prevents thromboembolic disorders such as deep vein thrombosis and pulmonary embolism in at‑risk patients.

GNH USA supplies Innohep as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Innohep, a low molecular weight heparin, is used in several thrombo‑vascular conditions.

- Deep vein thrombosis (DVT) prophylaxis: prevents clot formation in surgical and immobilised patients. - Acute deep vein thrombosis treatment: facilitates resolution of existing venous clots. - Pulmonary embolism prevention and treatment: reduces risk of embolic events in high‑risk individuals. - Acute coronary syndrome management: helps prevent further coronary thrombosis during the acute phase.

Common Side Effects: - Injection‑site bruising or pain. - Mild bleeding such as epistaxis or gum bleeding. - Nausea or gastrointestinal discomfort. - Headache or dizziness. - Transient elevation of liver enzymes. - Local erythema at the injection site.

Serious or Rare Side Effects: - Major hemorrhage (intracranial, gastrointestinal). - Heparin‑induced thrombocytopenia (HIT). - Severe allergic reactions including anaphylaxis. - Skin necrosis at injection sites. - Spinal or epidural hematoma following neuraxial procedures. - Thrombosis despite therapy (rebound clotting).

Before using Innohep, consider the following precautions.

- Renal impairment: assess renal function and adjust dose if necessary. - Hepatic dysfunction: monitor liver enzymes and coagulation parameters. - Concomitant anticoagulants or antiplatelet agents: increased risk of bleeding; use with caution. - Recent surgery or trauma: heightened bleeding risk; evaluate timing of administration. - Pregnancy and lactation: safety not established; weigh benefits against potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Innohep may interact with several medicines; monitor patients accordingly.

Major Interactions (Avoid): - Other anticoagulants (e.g., warfarin, direct oral anticoagulants): additive bleeding risk. - Thrombolytic agents (e.g., alteplase): may cause severe hemorrhage. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase gastrointestinal bleeding.

Moderate Interactions (Monitor Closely): - Antiplatelet drugs (e.g., clopidogrel): heightened bleeding tendency. - Certain antibiotics (e.g., vancomycin): may alter anticoagulant effect. - Corticosteroids: potential for mucosal bleeding. - ACE inhibitors or diuretics: monitor renal function and electrolytes.